Literature DB >> 16679556

alpha-Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress.

Nijee Sharma1, Katrina A Brandis, Sara K Herrera, Brandon E Johnson, Tulaza Vaidya, Ruja Shrestha, Shubhik K Debburman.   

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder that results from the selective loss of midbrain dopaminergic neurons. Misfolding and aggregation of the protein alpha-synuclein, oxidative damage, and proteasomal impairment are all hypotheses for the molecular cause of this selective neurotoxicity. Here, we describe a Saccharomyces cerevisiae model to evaluate the misfolding, aggregation, and toxicity-inducing ability of wild-type alpha-synuclein and three mutants (A30P, A53T, and A30P/A53T), and we compare regulation of these properties by dysfunctional proteasomes and by oxidative stress. We found prominent localization of wild-type and A53T alpha-synuclein near the plasma membrane, supporting known in vitro lipid-binding ability. In contrast, A30P was mostly cytoplasmic, whereas A30P/A53T displayed both types of fluorescence. Surprisingly, alpha-synuclein was not toxic to several yeast strains tested. When yeast mutants for the proteasomal barrel (doa3-1) were evaluated, delayed alpha-synuclein synthesis and membrane association were observed; yeast mutant for the proteasomal cap (sen3-1) exhibited increased accumulation and aggregation of alpha-synuclein. Both sen3-1and doa3-1 mutants exhibited synthetic lethality with alpha-synuclein. When yeasts were challenged with an oxidant (hydrogen peroxide), alpha-synuclein was extremely lethal to cells that lacked manganese superoxide dismutase Mn-SOD (sod2Delta) but not to cells that lacked copper, zinc superoxide dismutase Cu,Zn-SOD (sod1Delta). Despite the toxicity, sod2Delta cells never displayed intracellular aggregates of alpha-synuclein. We suggest that the toxic alpha-synuclein species in yeast are smaller than the visible aggregates, and toxicity might involve alpha-synuclein membrane association. Thus, yeasts have emerged effective organisms for characterizing factors and mechanisms that regulate alpha-synuclein toxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679556     DOI: 10.1385/JMN:28:2:161

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  84 in total

1.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch.

Authors:  J M George; H Jin; W S Woods; D F Clayton
Journal:  Neuron       Date:  1995-08       Impact factor: 17.173

2.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease.

Authors:  Y Mizuno; S Ohta; M Tanaka; S Takamiya; K Suzuki; T Sato; H Oya; T Ozawa; Y Kagawa
Journal:  Biochem Biophys Res Commun       Date:  1989-09-29       Impact factor: 3.575

3.  Selective neuronal vulnerability and inadequate stress response in superoxide dismutase mutant mice.

Authors:  Stephen Lynn; Eric J Huang; Sailaja Elchuri; Mohammed Naeemuddin; Yumiko Nishinaka; Junji Yodoi; Donna M Ferriero; Charles J Epstein; Ting-Ting Huang
Journal:  Free Radic Biol Med       Date:  2005-03-15       Impact factor: 7.376

4.  Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

Authors:  L Narhi; S J Wood; S Steavenson; Y Jiang; G M Wu; D Anafi; S A Kaufman; F Martin; K Sitney; P Denis; J C Louis; J Wypych; A L Biere; M Citron
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

5.  alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.

Authors:  N Ostrerova; L Petrucelli; M Farrer; N Mehta; P Choi; J Hardy; B Wolozin
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

6.  Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins.

Authors:  S Krobitsch; S Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.

Authors:  P J Kahle; M Neumann; L Ozmen; V Muller; H Jacobsen; A Schindzielorz; M Okochi; U Leimer; H van Der Putten; A Probst; E Kremmer; H A Kretzschmar; C Haass
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

8.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

9.  Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice.

Authors:  R M Lebovitz; H Zhang; H Vogel; J Cartwright; L Dionne; N Lu; S Huang; M M Matzuk
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation.

Authors:  Shoshana Shendelman; Alan Jonason; Cecile Martinat; Thomas Leete; Asa Abeliovich
Journal:  PLoS Biol       Date:  2004-10-05       Impact factor: 8.029

View more
  32 in total

Review 1.  SLipid-induced cell dysfunction and cell death: lessons from yeast.

Authors:  Sepp D Kohlwein; Julia Petschnigg
Journal:  Curr Hypertens Rep       Date:  2007-12       Impact factor: 5.369

Review 2.  Modeling ALS and FTLD proteinopathies in yeast: an efficient approach for studying protein aggregation and toxicity.

Authors:  Dmitry Kryndushkin; Frank Shewmaker
Journal:  Prion       Date:  2011-10-01       Impact factor: 3.931

3.  From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies.

Authors:  Jeff S Piotrowski; Daniel F Tardiff
Journal:  Methods Mol Biol       Date:  2019

4.  FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with TDP-43 in a yeast model of amyotrophic lateral sclerosis.

Authors:  Dmitry Kryndushkin; Reed B Wickner; Frank Shewmaker
Journal:  Protein Cell       Date:  2011-03-30       Impact factor: 14.870

Review 5.  Signaling pathways and posttranslational modifications of tau in Alzheimer's disease: the humanization of yeast cells.

Authors:  Jürgen J Heinisch; Roland Brandt
Journal:  Microb Cell       Date:  2016-03-25

6.  alpha-Synuclein fission yeast model: concentration-dependent aggregation without plasma membrane localization or toxicity.

Authors:  Katrina A Brandis; Isaac F Holmes; Samantha J England; Nijee Sharma; Lokesh Kukreja; Shubhik K DebBurman
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

7.  Assessment of Cytotoxicity of α-Synuclein in Budding Yeast Using a Spot Growth Assay and Fluorescent Microscopy.

Authors:  Masak Takaine
Journal:  Methods Mol Biol       Date:  2021

8.  Clearance and phosphorylation of alpha-synuclein are inhibited in methionine sulfoxide reductase a null yeast cells.

Authors:  Derek B Oien; Heather E Shinogle; David S Moore; Jackob Moskovitz
Journal:  J Mol Neurosci       Date:  2009-08-04       Impact factor: 3.444

9.  Hsp31 Is a Stress Response Chaperone That Intervenes in the Protein Misfolding Process.

Authors:  Chai-Jui Tsai; Kiran Aslam; Holli M Drendel; Josephat M Asiago; Kourtney M Goode; Lake N Paul; Jean-Christophe Rochet; Tony R Hazbun
Journal:  J Biol Chem       Date:  2015-08-25       Impact factor: 5.157

Review 10.  Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities.

Authors:  Neena Singh; Swati Haldar; Ajai K Tripathi; Katharine Horback; Joseph Wong; Deepak Sharma; Amber Beserra; Srinivas Suda; Charumathi Anbalagan; Som Dev; Chinmay K Mukhopadhyay; Ajay Singh
Journal:  Antioxid Redox Signal       Date:  2013-08-15       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.